Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
Go back to Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 242.38 -4.43 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $246.81 | 52 Week High | $160.00 | |||
| Open | $240.00 | 52 Week Low | $95.80 | |||
| Day High | $244.71 | P/E | 45.05 | |||
| Day Low | $240.00 | EPS | $5.38 | |||
| Volume | 78,754 | |||||
